Payload Information
General Information of This Payload
| Payload ID | PAY0UGLKQ |
|||||
|---|---|---|---|---|---|---|
| Name | RU2833323C1+Hu63-13-2-A+payload |
|||||
| Synonyms |
RU2833323C1+Hu63-13-2-A+payload
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C30H31FN4O6 |
|||||
| Isosmiles | CC1=C(F)C=C2C3=C1CC[C@H](NC([C@H](OCN)C4CC4)=O)C3=C(C(C5=CC([C@@]6(O)CC)=C7COC6=O)=N2)CN5C7=O |
|||||
| InChI |
InChI=1S/C30H31FN4O6/c1-3-30(39)18-8-22-25-16(10-35(22)28(37)17(18)11-40-29(30)38)24-20(34-27(36)26(41-12-32)14-4-5-14)7-6-15-13(2)19(31)9-21(33-25)23(15)24/h8-9,14,20,26,39H,3-7,10-12,32H2,1-2H3,(H,34,36)/t20-,26+,30-/m0/s1
|
|||||
| InChIKey |
UGTGLDLIIGUWBO-AQDMSIBGSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
562.598 |
Polar area |
145.77 |
||
Complexity |
1681.906719 |
xlogp Value |
2.34202 |
|||
Heavy Count |
41 |
Rot Bonds |
6 |
|||
Hbond acc |
9 |
Hbond Donor |
3 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
Hu103-32-2-A (1) [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
2.374 nM
|
Moderate CEACAM5 expression (CEACAM5++) | ||
| Method Description |
A Cell line test on LS174T
|
||||
| In Vitro Model | Colon adenocarcinoma | LS174T cells | CVCL_1384 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
2.998 nM
|
High CEACAM5 expression (CEACAM5 +++) | ||
| Method Description |
A Cell line test on MKN45
|
||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
78.1 nM
|
Negative CEACAM5 expression (CEACAM5-) | ||
| Method Description |
A Cell line test on HCT116
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
1.79 nM
|
High CEACAM5 expression (CEACAM5 +++) | ||
| Method Description |
A Cell line test on MKN45
|
||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
Hu103-32-2-A (2) [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
2.863 nM
|
High CEACAM5 expression (CEACAM5 +++) | ||
| Method Description |
A Cell line test on MKN45
|
||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
3.076 nM
|
Moderate CEACAM5 expression (CEACAM5++) | ||
| Method Description |
A Cell line test on LS174T
|
||||
| In Vitro Model | Colon adenocarcinoma | LS174T cells | CVCL_1384 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
83.58 nM
|
Negative CEACAM5 expression (CEACAM5-) | ||
| Method Description |
A Cell line test on HCT116
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
Hu67-14-2-A (1) [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
3.331 nM
|
High CEACAM5 expression (CEACAM5 +++) | ||
| Method Description |
A Cell line test on MKN45
|
||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
9.236 nM
|
Moderate CEACAM5 expression (CEACAM5++) | ||
| Method Description |
A Cell line test on LS174T
|
||||
| In Vitro Model | Colon adenocarcinoma | LS174T cells | CVCL_1384 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
71.83 nM
|
Negative CEACAM5 expression (CEACAM5-) | ||
| Method Description |
A Cell line test on HCT116
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
Hu63-13-2-A (1) [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
3.933 nM
|
High CEACAM5 expression (CEACAM5 +++) | ||
| Method Description |
A Cell line test on MKN45
|
||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
13.08 nM
|
Moderate CEACAM5 expression (CEACAM5++) | ||
| Method Description |
A Cell line test on LS174T
|
||||
| In Vitro Model | Colon adenocarcinoma | LS174T cells | CVCL_1384 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
87.64 nM
|
Negative CEACAM5 expression (CEACAM5-) | ||
| Method Description |
A Cell line test on HCT116
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
2.93 nM
|
High CEACAM5 expression (CEACAM5 +++) | ||
| Method Description |
A Cell line test on HEK293T
|
||||
| In Vitro Model | Normal | HEK293T cells | CVCL_0063 | ||
Hu47-14-2-A [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
6.58 nM
|
High CEACAM5 expression (CEACAM5 +++) | ||
| Method Description |
A Cell line test on MKN45
|
||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
10.3 nM
|
Moderate CEACAM5 expression (CEACAM5++) | ||
| Method Description |
A Cell line test on LS174T
|
||||
| In Vitro Model | Colon adenocarcinoma | LS174T cells | CVCL_1384 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
106.3 nM
|
Negative CEACAM5 expression (CEACAM5-) | ||
| Method Description |
A Cell line test on HCT116
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
4.19 nM
|
High CEACAM5 expression (CEACAM5 +++) | ||
| Method Description |
A Cell line test on MKN45
|
||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
Hu67-14-2-A (2) [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
9.388 nM
|
High CEACAM5 expression (CEACAM5 +++) | ||
| Method Description |
A Cell line test on MKN45
|
||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
15.58 nM
|
Moderate CEACAM5 expression (CEACAM5++) | ||
| Method Description |
A Cell line test on LS174T
|
||||
| In Vitro Model | Colon adenocarcinoma | LS174T cells | CVCL_1384 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
71.95 nM
|
Negative CEACAM5 expression (CEACAM5-) | ||
| Method Description |
A Cell line test on HCT116
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Effective Concentration (EC50) |
1.58 nM
|
High CEACAM5 expression (CEACAM5 +++) | ||
| Method Description |
A Cell line test on MKN45
|
||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
Hu63-13-2-A (2) [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
34.02 nM
|
High CEACAM5 expression (CEACAM5 +++) | ||
| Method Description |
A Cell line test on MKN45
|
||||
| In Vitro Model | Gastric adenocarcinoma | MKN45 cells | CVCL_0434 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
34.03 nM
|
Moderate CEACAM5 expression (CEACAM5++) | ||
| Method Description |
A Cell line test on LS174T
|
||||
| In Vitro Model | Colon adenocarcinoma | LS174T cells | CVCL_1384 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
165.1 nM
|
Negative CEACAM5 expression (CEACAM5-) | ||
| Method Description |
A Cell line test on HCT116
|
||||
| In Vitro Model | Colon carcinoma | HCT116 cells | CVCL_0291 | ||